Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two Days

This article was originally published in The Pink Sheet Daily

Executive Summary

Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.

Advertisement

Related Content

Pfizer Loses Fight To Persuade NICE Of Xalkori’s Cost-Effectiveness
No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials
No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials
Germany’s IQWiG Pans Pfizer’s Xalkori On Study Results, Side Effects
Pfizer’s Inlyta Shows Greater Efficacy In Subpopulation; Will It Be Enough For ODAC And FDA?
Pfizer’s Crizotinib Eases Past FDA With Targeted Population

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel